Efficacy and side‐effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders
- 22 December 2004
- journal article
- Published by Wiley in Nephrology
- Vol. 9 (6) , 406-413
Abstract
SUMMARY: Background: Poor phosphate control is common among patients with end‐stage renal disease. Sevelamer hydrochloride has been demonstrated to be a safe and effective phosphate binder when used as a monotherapy. However, cost limits its usefulness in many countries. Data assessing its effectiveness and safety in combination with conventional phosphate binders are lacking.Methods: Dialysis patients meeting the following inclusion criteria participated in this study: (i) hyperphosphataemia >1.8 mmol/L (5.6 mg/dL); and (ii) an inability to tolerate currently available binders. The trial was conducted in three phases each lasting 3 months: (i) an observation phase (patients continued on their regular phosphate binders); (ii) a titration phase (sevelamer was added at a dose of 403 mg three times daily with meals, titrated to a maximum of 1209 mg three times daily); and (iii) a maintenance phase.Results: Twenty‐five patients were recruited into the study. Eighteen patients completed all three trial phases. Mean serum phosphate dropped from 2.11 ± 0.06 mmol/L (6.6 ± 0.2 mg/dL) during the observation period to 1.91 ± 0.01 mmol/L (5.9 ± 0.003 mg/dL) during the maintenance phase (P = 0.02). Calcium × phosphate product fell from 5.49 ± 0.17 mmol2/L2 (68.64 ± 2.11 mg2 dL2) to 4.89 ± 0.27 mmol2/L2 (61.36 ± 3.35 mg2 dL2) (P = 0.02). There was no significant change in serum calcium or parathyroid hormone. Total serum cholesterol fell from 3.8 mmol/L (3.4–4.37) 147 mg/dL (131–169) to 3.55 mmol/L (2.97–4.2) 137 mg/dL (115–162) (P = 0.02). Serum low‐density lipoprotein cholesterol also fell significantly from 1.67 ± 0.10 mmol/L (65 ± 4 mg/dL) to 1.52 ± 0.11 mmol/L (59 ± 4 mg/dL) (P = 0.04). The average prescribed dose of sevelamer was 2.4 g/day. Elemental calcium dropped from 3.4 g/day (1.4 to 4.6) to 1.2 g/day (0.6–2.4) (P = 0.04). Seventy‐two per cent of patients reported mild flatulence, nausea and indigestion. Three patients discontinued treatment because of adverse effects.Conclusions: Sevelamer in combination with conventional phosphate binders is effective in lowering serum phosphate and calcium‐phosphate product in patients with refractory hyperphosphataemia. Beneficial effects on lipid profile were also observed. Mild gastrointestinal upset is common.Keywords
This publication has 18 references indexed in Scilit:
- Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patientsAdvances in Renal Replacement Therapy, 2003
- A prospective study of combination therapy for hyperphosphataemia with calcium-containing phosphate binders and sevelamer in hypercalcaemic haemodialysis patientsNephrology Dialysis Transplantation, 2002
- Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patientsKidney International, 2002
- Phosphate binders in uraemia: pharmacodynamics, pharmacoeconomics, pharmacoethicsNephrology Dialysis Transplantation, 2002
- Sevelamer, a Phosphate-Binding Polymer, is a Non-Absorbed CompoundClinical Pharmacokinetics, 2002
- Transient decrease of serum bicarbonate levels with Sevelamer hydrochloride as the phosphate binderKidney International, 2000
- Long-term effects of sevelamer hydrochloride on the calcium × phosphate product and lipid profile of haemodialysis patients*Nephrology Dialysis Transplantation, 1999
- RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormoneKidney International, 1999
- Calcific uremic arteriolopathy (calciphylaxis): An evolving entity?American Journal of Kidney Diseases, 1998
- Poly[allylamine hydrochloride] (RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failureAmerican Journal of Kidney Diseases, 1997